Indication
Sarcomatoid mesothelioma
2 clinical trials
3 drugs
Clinical trial
A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant MesotheliomaStatus: Active (not recruiting), Estimated PCD: 2026-03-20
Drug
mFOLFOX6Clinical trial
Official Title Neoadjuvant Immunotherapy in Sarcomatoid MesotheliomaStatus: Recruiting, Estimated PCD: 2024-12-15
Drug
T-VECDrug
Lurbinectedin